Article Figures & Data
- Supplementary Text, Supplementary Figures 1 through 13, Supplementary Methods - Supplementary text S1. Supplementary Figure 1: Chromatin Profiles of Primary GC. Supplementary Figure 2: Epithelial features of GC promoters. Supplementary Figure 3: GC Somatic Promoter Features. Supplementary Figure 4: Association of Somatic Promoters with Gene Expression in GC and Other Tumor Types. Supplementary Figure 5: Changes in DNA methylation at CpG island containing promoters. Supplementary Figure 6: Expression distribution of alternative and canonical isoforms. Supplementary Figure 7: Characterization of RASA3 Isoform. Supplementary Figure 8: Characterization of MET Isoforms. Supplementary Figure 9: Immunogenicity of N-terminal peptides. Supplementary Figure 10: Immunogenicity Assay and Nanostring Profiling. Supplementary Figure 11: Functional Assessment of Peptide Immunogenicity. Supplementary Figure 12: EZH2 Inhibition. Supplementary Figure 13: Unannotated somatic promoters.
- Supplementary Tables 1 through 13 - Supplementary Table 1: Clinicopathological Parameters of samples used Supplementary Table 2: Read Mapping Statistics of NanoChIP-seq Libraries Supplementary Table 3: Non coding RNAs associated with Somatic Promoters Supplementary Table 4: Alternative Promoters Supplementary Table 5: Spectral Counts from CRC samples of N terminal peptides predicted to be gained in GC Supplementary Table 6: HLA prediction of GC samples Supplementary Table 7: Recurrent N terminal sequences with high affinity to MHC Class I Supplementary Table 8: P values of Wilcoxon test between ACRG samples with high and low somatic promoter usage Supplementary Table 9: HLA types of healthy PBMC donors Supplementary Table 10: Peptide pools for alternative promoters Supplementary Table 11: Cytokine Responses of N terminal Peptides Supplementary Table 12: Somatic Promoters Overlapping EZH2/SUZ12 Binding Sites Supplementary Table 13: RACE Primers